| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
| US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(3 years ago) | |
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
|
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(3 years ago) | |
|
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(8 months ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(8 days ago) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(8 days ago) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 10 months from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(2 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(2 years from now) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(2 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(2 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(6 years from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(7 years from now) | |
Dexilant is owned by Takeda Pharms Usa.
Dexilant contains Dexlansoprazole.
Dexilant has a total of 25 drug patents out of which 13 drug patents have expired.
Expired drug patents of Dexilant are:
- US6939971
- US7285668*PED
- US6939971*PED
- US6462058*PED
- US6664276*PED
- US8784885
- US8722084
- US8722084*PED
- US8784885*PED
- US9145389
- US6462058
- US7285668
- US6664276
Dexilant was authorised for market use on 30 January, 2009.
Dexilant is available in capsule, delayed release;oral dosage forms.
Dexilant can be used as for healing of all grades of erosive esophagitis (ee), healing of all grades of erosive esophagitis (ee) for up to 8 weeks, use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions, treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks, maintain healing of erosive esophagitis (ee) for up to 6 months, to maintain healing of ee and relief of heartburn.
The generics of Dexilant are possible to be released after 05 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; For healing of all grades of erosive esophagitis (ee); Healing of all grades of erosive esophagit...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
